Two charged over counterfeit Ozempic pens behind FDA's 2023 public alert
Court documents say the men sourced fake pens, labels and needles from unauthorized Chinese suppliers and kept selling after the FDA warning.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 5 03:00 ETSource: Partnership for Safe Medicines
The wire
- 01Two Indian nationals were charged in connection with counterfeit Ozempic pens that prompted a December 2023 FDA alert; the alleged scheme ran from July 2023 to April 2024 and continued after the warning.
- 02Court documents say more than 150 pharmacies and businesses were victimized, a direct sourcing risk for dispensers handling semaglutide pens.
- 03One defendant was extradited from Italy and the other remains at large; each faces a maximum of 71 years if convicted, and the charges are allegations.
From the source
Read at safemedicines.orgOctober 5, 2026: Two charged in connection with fake Ozempic that spurred FDA public alert
Two Indian nationals were charged in connection with counterfeit Ozempic pens that spurred a December 2023 public warning from the FDA . According to court documents , from at least July 2023 to April 2024, the men allegedly obtained the counterfeit products, which included the packaging, pen labels, and needles, from unauthorized sources in China. Even after the FDA’s warning, the scheme allegedl
